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Hepatitis C transmission and treatment as prevention – the role of the injecting network 
 
Highlights 
• Injecting networks powerfully influence HCV transmission; in particular, injecting 
relationships are strongly correlated with HCV transmission clusters. 
• Real-world injecting networks restrict HCV transmission relative to the fully connected 
homogenous populations assumed in most models. 
• Targeting treatment using a “bring your friends” approach is more effective than 
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transmission. In this paper we provide an overview of 10 years of research into injecting 
networks and HCV, culminating in a network-based approach to provision of direct-acting 
antiviral therapy.  
Methods 
Between 2005 and 2010 we followed a cohort of 413 PWID, measuring HCV incidence, 
prevalence and injecting risk, including network-related factors. We developed an individual-
based HCV transmission model, using it to simulate the spread of HCV through the empirical 
social network of PWID. In addition, we created an empirically grounded network model of 
injecting relationships using exponential random graph models (ERGMs), allowing 
simulation of realistic networks for investigating HCV treatment and intervention strategies. 
Our empirical work and modelling underpins the TAP study, which is examining the 
feasibility of community-based treatment of PWID with DAAs.  
Results 
We observed incidence rates of HCV primary infection and reinfection of 12.8 per 100 
person-years (PY) (95%CI: 7.7–20.0) and 28.8 per 100 PY (95%CI: 15.0–55.4) respectively, 
and determined that HCV transmission clusters correlated with reported injecting 
relationships. Transmission modelling showed that the empirical network provided some 
protective effect, slowing HCV transmission compared to a fully connected, homogenous 
PWID population. Our ERGMs revealed that treating PWID and all their contacts was the 
most effective strategy and targeting treatment to infected PWID with the most contacts the 
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Networks-based approaches greatly increase understanding of HCV transmission and will 
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The hepatitis C virus (HCV) is a major health issue leading to significant morbidity and 
mortality, affecting an estimated 184 million people globally (Mohd Hanafiah, Groeger, 
Flaxman, & Wiersma, 2013). In more developed countries like Australia the epidemic is 
driven by people who inject drugs (PWID) (Mohd Hanafiah et al., 2013; Shepard, Finelli, & 
Alter, 2005). To reduce transmission of HCV it is important to understand the specific risk 
factors that drive it; some are individual behaviours like sharing needles and syringes, and 
others are related to the context in which injecting occurs (Morris et al., 2014). The injecting 
network – the pattern of relationships between people who inject drugs – is a contextual 
factor that powerfully influences HCV transmission. 
For the past 10 years our group (comprising epidemiologists, immune-virologists, 
mathematical and network modellers and a team of field researchers experienced in working 
with PWID) has examined the role of the injecting network in influencing HCV transmission 
and explored network-related strategies to reduce disease transmission. This paper provides 
an overview of that research and briefly describes the Hepatitis C Treatment and Prevention 
(TAP) Study, which evaluates the effect of a network-based approach to provision of direct-
acting antiviral (DAA) therapy on HCV prevalence and incidence.  
Tracing HCV in networks of PWID 
Between 2005 and 2010 we followed a cohort of PWID measuring HCV incidence, 
prevalence and injecting risk, including network-related factors (Aitken et al., 2008; Miller, 
Hellard, Bowden, Bharadwaj, & Aitken, 2009; Sacks-Davis et al., 2012). Four hundred and 




Hellard, M., McBryde, E., Sacks-Davis, R., Rolls, D., Higgs, P., Aitken, C., Thompson, A., Doyle, J., Pattison, P., 
Robbins, G. Hepatitis C transmission and treatment as prevention – modelling the role of the injecting 
network, International Journal of Drug Policy, 
 
 
transmission of hepatitis C, hepatitis B virus (HBV) and HIV. Participants completed detailed 
questionnaires on their drug use and risk behaviours, provided blood samples for serology 
testing, and were asked to nominate up to five injecting partners at each interview for the first 
three years of the study. Their nominated injecting partners were then recruited into the study 
(if possible) through direct introduction or data matching following independent encounters 
(Aitken et al., 2008; Sacks-Davis et al., 2012). The baseline prevalences of HCV, HBV and 
HIV were 70%, 34% and <1% respectively: the prevalences of HIV/HCV and HBV/HIV co-
infection were <1% and 2% respectively (Miller et al., 2009). HCV primary infection and 
reinfection were examined in a subset of 188 participants; the incidence of primary infection 
was 12.8 per 100 person-years (PY) (95%CI: 7.7–20.0), reinfection was 28.8 per 100 PY 
(95%CI: 15.0–55.4) (Sacks-Davis et al., 2013).  
We hypothesised that, within our cohort, HCV transmission occurred most often between 
people who reported injecting drugs together (at the same time, in the same space); this 
facilitates exposure to blood, and hence HCV, through needle-sharing and other behaviours. 
We studied HCV phylogeny within the cohort – that is, the genetic similarity (or relatedness)  
of the HCV sequences of our participants – and compared it with information about social-
injecting relationships in the same group (Sacks-Davis et al., 2012). The phylogenetic 
component of the study used sequencing of the HCV core region. Genetic clusters were 
identified using bootstrapping (cut-off: 70%). An adjusted Jaccard similarity coefficient was 
used to measure the association between the reported injecting relationships and relationships 
defined by clustering in the phylogenetic analysis (We observed 244 HCV infections in 238 
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study entry and 40% of participants with newly acquired infections had molecular evidence 
of related infections with at least one injecting partner. A key finding was that likely 
transmission clusters identified in phylogenetic analysis correlated with reported injecting 
relationships (adjusted Jaccard coefficient: 0.300; p<0.001). Importantly, this was the first 
study to prove that HCV phylogeny was associated with the injecting network, highlighting 
its importance in HCV transmission (Sacks-Davis et al., 2012).   
Modelling network influence on HCV transmission  
In addition to establishing empirically that the social-injecting network was related to the 
HCV transmission network using phylogenetic analysis, we wanted to understand how the 
social network affected HCV transmission. We used mathematical modelling to explore this 
phenomenon in detail. First, we developed an individual-based HCV transmission model that 
could be applied to a social network of PWID (Rolls et al., 2012). We then used this model to 
simulate the transmission of HCV through the empirical social network of PWID observed in 
our study. A feature of our model is that sources of infection can be both network neighbours 
and non-neighbours via “importing” HCV; this was important to account for infection being 
introduced from outside the described network.  
Key findings were that the empirical social network provided some protective effect on the 
time to primary HCV infection compared to an appropriately calibrated fully connected 
network which replicates thorough, instantaneous “mixing” of the population (mixing is an 
assumption built into dynamic compartmental models) (Andersson & Britton, 2000; 
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network, with a mean time to infection of 337 (95% CI: 334 – 349) days in the empirical 
social network compared to 272 (95% CI: 270 – 273) days in a fully connected network 
(Rolls et al, 2012). The incidence rates of infection across and between nodes (PWID) also 
differed within the model: we determined that individuals were at greater risk of infection if 
they had a higher frequency of injecting and more network partners (Figure 1) (Rolls et al., 
2012). Another important observation in the model was that in the case of “gateway” nodes to 
a sub-network, the time to next infection in the sub-network was significantly greater when 
the gateway node cleared HCV spontaneously than if chronically infected. This suggests that 
if a gateway node can be “turned off” (i.e., made HCV RNA negative and therefore non-
infectious) via spontaneous clearance or treatment, this substantially reduces the rate of HCV 
transmission through a part of the network.   
 
Figure 1. Simulation results for incidence of HCV by number of network partners 
(nodes) and frequency of injecting. As expected, incidence increases with additional 
injecting partners and higher frequency of injecting. (Rolls et al., 2012)  
 
Simulation of HCV treatment 
A further objective was to learn how HCV is transmitted in social networks of injectors and 
identify strategies that could be used to reduce the frequency of HCV transmissions. To this 
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empirically grounded network model of who might inject with whom (injecting occurs at the 
same time and space) using exponential random graph models (ERGMs). ERGMs are based 
on theories of social network formation, and can be used to simulate new networks with 
similar characteristics to empirically observed social networks. Because the network data 
resembled a snowball sample, model fitting required a recent technique developed for fitting 
ERGMs to snowball samples to avoid bias that may arise from ignoring the snowball nature 
of the data. In this case, the characteristics modelled included network features like 
transitivity (i.e., the friend of my friend is also my friend) and social circuit dependence (i.e., 
if the partners of individuals X and Y are connected then X and Y themselves are more likely 
to be connected).  Four attributes (location, age, injecting frequency, gender) were also 
included in the model to capture aspects of homophily (i.e., “friends of a feather” flock 
together). The network parameter estimates were then used to create a novel model-
dependent estimate of the size of the target population. The results made it possible to 
simulate realistic networks for investigating treatment and intervention strategies for reducing 
HCV prevalence (Rolls et al., 2013b).  
Using these simulated networks, and focusing on large connected components of similar size 
as the most interesting for research into transmission, we examined HCV transmission and 
treatment, including the impact of spontaneously clearing nodes. Treatments were 
parameterised in anticipation of upcoming DAAs. With regard to transmission, as with our 
previous mathematical model, both the number of contacts (injecting partners) and injecting 
frequency were associated with reducing the time to primary infection and HCV incidence. 
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one additional network contact (Rolls et al., 2013a). In controlled comparisons, nodes that 
cleared their HCV infection (as would occur if a person was successfully treated) had a local 
effect on infection risk compared with nodes that did not. The total number of spontaneously 
clearing nodes, but not their specific location, had a network-wide effect on HCV primary 
and reinfection incidence. We then investigated the effect of various network-based HCV 
treatment strategies on incidence rates, with reinfection playing a large role in the 
effectiveness of treatment interventions. Strategies that treated PWID and all their contacts, 
analogous to ring vaccination, were the most effective in reducing the incidence rates of 
reinfection and combined infection. The strategy targeting infected PWID with the most 
contacts, analogous to targeted vaccination, was the least effective (Rolls et al., 2013a). This 
is in contrast to the widespread belief that targeted vaccination is generally the most effective 
vaccination strategy. 
Next we examined how using a networks-based approach to treat PWID affects HCV 
prevalence. We created networks of 10 480 nodes by using an ERGM to simulate 20 
subnetworks of 524 nodes at a time (Hellard et al., 2014). We then simulated transmission of 
HCV through these networks using a discrete time stochastic transmission model. Informed 
by dynamic transmission models developed by Martin and Vickerman (Martin et al., 2013), 
we modelled treatment of 15/1000, 25/1000 and 50/1000 PWID per year over 10 and 20 
years using treatment efficacies of 60% and 80%. The effect of five treatment strategies on 
the prevalence of HCV was investigated: (1) treat highest-degree nodes first, (2) treat most 
uninfected neighbours first (3) treat least infected neighbours first (4) treat randomly selected 
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all their infected neighbours are treated (Figure 2). While the network-wide information that 
would enable strategies 1-3 (i.e., everyone’s number of contacts, everyone’s infection status) 
would generally not be available, they serve as important comparisons. The “bring your 
friends” strategy was considered plausible for use in a clinical setting. 
 
Figure 2: Four treatment strategies using a network based approach (Hellard et al., 
2014) . 
 
As treatment coverage increased, HCV prevalence at 10 years reduced for both the 60% and 
80% efficacy treatment. Within each set of parameters, the bring your friends strategy 
performed better than the random strategy, being most marked for higher-efficacy treatment. 
For example, over 10 years of treating 25 per 1,000 PWID at 80% treatment efficacy, HCV 
prevalence dropped from 50% to 40% using the random strategy and from 50% to 33% using 
the treat your friends strategy (6.5% difference; 95%CI: 5.1–8.1). (Figure 3). The bring your 
friends strategy was proposed because it seemed the most plausible real-world treatment 
strategy; most PWID will be unaware of the structure of their injecting network, but they 
know their immediate injecting partners. It seems reasonable to assume these injecting 
partners could be treated at the same time as the primary PWID, particularly with the advent 
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Figure 3 Impact of hepatitis C treatment at 10 years with 80% treatment efficacy with 
coverage of 25 per 1,000 PWID per year. (Hellard et al., 2014)  
 
Application of models to clinical trials 
Informed by the results of our models, between 2014 and 2016 we are undertaking the 
Hepatitis C Treatment and Prevention (TAP) Study. The TAP study is designed to examine 
the feasibility of treating PWID in a community-based setting with a 12-week course of oral 
therapy that combines the DAAs sofosbuvir and ledipasvir (SOF + LDP) for participants 
infected with genotype 1 and SOF +LDP and ribavirin (Rib) for participants infected with all 
other genotypes. Another key aim of the study is to measure the effect of treating PWID 
using a “bring your friends” strategy to determine whether a network-based treatment 
approach impacts on rates of HCV primary infection and reinfection and reduces HCV 
prevalence among PWID. Participants are being sourced from the Burnet Institute’s existing 
SuperMIX cohort, which comprises over 700 PWID, most with chronic HCV infection 
(Horyniak et al., 2013).  
The TAP study comprises primary and secondary participants who are randomised to three 
treatment arms (Figure 4). Primary participants will be recruited from the SuperMIX cohort 
(n=120; 40 in each arm) and will be current PWID (injected last six months) and HCV RNA 
positive. Secondary participants (n=300; 100 in each arm) are current injecting partners of the 
primary participants identified using the “bring your friends” strategy, and will include a mix 
of HCV-positive and HCV-negative individuals Group A comprises primary and secondary 
participants who receive supportive care for 18 months. Examples of supportive care are 
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B vaccine if appropriate.  In Group B, all primary participants will be treated with SOF + 
LDP (+/- RBV) for 12 weeks immediately and secondary participants receive supportive care 
only. In Group C, all  primary participants, and those secondary participants with chronic 
HCV infection, will be treated with SOF + LDP (+/- RBV) for 12 weeks immediately; any 
Group C participants with primary infection or reinfection during the study will also receive 
immediate (re-)treatment. 
 
Figure 4.  Treatment strategy for the three arms of the TAP Study 
 
Participants will be followed for 18 months after treatment, with the incidence of HCV 
primary infection and reinfection being measured every three months; at the end of the study 
HCV incidence will be compared across the three groups. Molecular sequencing will be 
undertaken to identify the probable sources of any reinfection events. At the completion of 
the study all participants who received supportive care will be offered treatment with SOF + 
LDP (+/- RBV). 
The TAP Study will produce vital and novel data for future public health and treatment 
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Our work highlights the importance of using a networks-based approach to increase our 
understanding of HCV transmission and its role in informing the roll out of treatment as 
prevention. Nevertheless, we are yet to determine how differences in injecting networks, such 
as variation in the network structure, injecting risk behaviour and HCV prevalence, alter the 
influence of the injecting network. Further research is required to understand the broader 
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